Boston Scientific subsidiary prices €1.5B senior notes to refinance 2025 maturity

BOSTON SCIENTIFIC CORP

AMS Europe issued €850M 3.000% notes due 2031 and €650M 3.250% notes due 2034.
Net proceeds of approximately €1.487B after underwriting discount and expenses.
Proceeds will fund repayment of AMS Europe's 0.750% notes due March 8, 2025.
Remaining proceeds for general corporate purposes including acquisitions.
Notes are fully and unconditionally guaranteed by Boston Scientific.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.